AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12570326 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33
Study 10512688 — intervention group
Group type: EXPERIMENTAL
Intervention: GHD patients
Number of subjects: 0
Study 10512688 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 7727665 — intervention group
Group type: EXPERIMENTAL
Intervention: S. epidermidis bacteremia in the NICU
Number of subjects: 56
Study 7727665 — intervention group
Group type: COMPARATOR
Intervention: Control strains from other patients with bacteremia
Number of subjects: 56
Study 2282994 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol
Number of subjects: 145
Study 2282994 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 145
Study 2282994 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (Control)
Number of subjects: 145
Study 30683697 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept treatment
Number of subjects: 0
Study 30514400 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 750
Study 30514400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study 27333006 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 12
Study 27333006 — intervention group
Group type: COMPARATOR
Intervention: Rotary instruments
Number of subjects: 12
Study 25299601 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Grain (WG) diet
Number of subjects: 20
Study 25299601 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Meat (RM) diet
Number of subjects: 20
Study 22679525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide-albendazole (1,000 mg-400 mg)
Number of subjects: 533
Study 22679525 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg)
Number of subjects: 533
Study 22679525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (1,000 mg)
Number of subjects: 533
Study 22679525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 533
Study 19849767 — intervention group
Group type: EXPERIMENTAL
Intervention: AMC/DCBA throat lozenges (n = 155)
Number of subjects: 310
Study 19849767 — intervention group
Group type: COMPARATOR
Intervention: Non‐medicated placebo lozenges (n = 155)
Number of subjects: 310
Study 18254322 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine stimulating group
Number of subjects: 0
Study 18254322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone group
Number of subjects: 0
Study 18254322 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 15563561 — intervention group
Group type: COMPARATOR
Intervention: Conventional HD (control)
Number of subjects: 11
Study 15563561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium balance-positive step-down sodium profiling HD (PS)
Number of subjects: 11
Study 15563561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium balance-neutral step-down sodium profiling HD (NS)
Number of subjects: 11
Study 15563561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium balance-neutral alternating sodium profiling HD (NA)
Number of subjects: 11
Study 15563561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration only (UF only)
Number of subjects: 11
Study 15563561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium balance-positive step-down sodium profiling HD with ultrafiltration (PS+U)
Number of subjects: 11
Study 15563561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium balance-neutral step-down sodium profiling HD with ultrafiltration (NS+U)
Number of subjects: 11
Study 15563561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium balance-neutral alternating sodium profiling HD with ultrafiltration (NA+U)
Number of subjects: 11
Study 12393777 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 4‐8 mg kg(‐1) h(‐1) (group P; n=16)
Number of subjects: 33
Study 12393777 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5‐2.5 vol% sevoflurane (group S; n=17)
Number of subjects: 33
Study 12393777 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Propofol and Sevoflurane)
Number of subjects: 33
Study 10439497 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 370
Study 10439497 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 370
Study 10439497 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 370
Study 10439497 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 370
Study 7786943 — intervention group
Group type: EXPERIMENTAL
Intervention: Appointment-letter invitation
Number of subjects: 757
Study 7786943 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter-only invitation
Number of subjects: 757
Study 7786943 — intervention group
Group type: COMPARATOR
Intervention: Tagged-notes intervention
Number of subjects: 757
Study 7786943 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 757
Study 2187445 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose prophylaxis with cefotiam and metronidazol
Number of subjects: 114
Study 2187445 — intervention group
Group type: COMPARATOR
Intervention: 24-hour prophylaxis with cefotiam and metronidazol
Number of subjects: 114
Study 6163389 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting zinc-protamine-glucagon (7.5 mg every 12 hours for 4-5 days)
Number of subjects: 71
Study 6163389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 31385333 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 414
Study 31385333 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral health education (CE)
Number of subjects: 414
Study 28686774 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary acne lesions (papules, pustules, comedones)
Number of subjects: 32
Study 28686774 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythematous macules or hyperpigmentation
Number of subjects: 32
Study 28686774 — intervention group
Group type: EXPERIMENTAL
Intervention: Papules and pustules
Number of subjects: 32
Study 28686774 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of papules
Number of subjects: 32
Study 28686774 — intervention group
Group type: EXPERIMENTAL
Intervention: Scars remaining at 6 months
Number of subjects: 32
Study 26665288 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm & Hammer Truly Radiant Toothpaste
Number of subjects: 182
Study 26665288 — intervention group
Group type: COMPARATOR
Intervention: Colgate Cavity Protection Toothpaste
Number of subjects: 182
Study 26665288 — intervention group
Group type: COMPARATOR
Intervention: Crest 3‐D White Radiant Mint Toothpaste
Number of subjects: 182
Study 23892409 — intervention group
Group type: COMPARATOR
Intervention: Luminal A
Number of subjects: 3381
Study 23892409 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-negative
Number of subjects: 3381
Study 23892409 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-enriched
Number of subjects: 3381
Study 23892409 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 3381
Study 21297191 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐year twice‐weekly weight training intervention
Number of subjects: 0
Study 19397667 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpurpuragenic pulsed dye laser (PDL)
Number of subjects: 29
Study 19397667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL)
Number of subjects: 29
Study 19397667 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 29
Study 16168151 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Self-Help (GSH)
Number of subjects: 109
Study 16168151 — intervention group
Group type: COMPARATOR
Intervention: Delayed Treatment Control (DTC)
Number of subjects: 109
Study 12968987 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene receptor antagonist
Number of subjects: 159
Study 12968987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 10535380 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated (POLY) diet
Number of subjects: 9
Study 10535380 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated (SAT) diet
Number of subjects: 9
Study 10535380 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated (MONO) diet
Number of subjects: 9
Study 10535380 — intervention group
Group type: COMPARATOR
Intervention: Feeding state (fed vs unfed)
Number of subjects: 9
Study 8739862 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water irrigation
Number of subjects: 44
Study 8739862 — intervention group
Group type: COMPARATOR
Intervention: Tamponade
Number of subjects: 44
Study 1880439 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine Transderm-V patches
Number of subjects: 13
Study 7102584 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 g glycerol
Number of subjects: 12
Study 7102584 — intervention group
Group type: COMPARATOR
Intervention: equicaloric amount of glucose solution
Number of subjects: 12
Study 7102584 — intervention group
Group type: COMPARATOR
Intervention: 30 ml of water
Number of subjects: 12
Study 31554628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 36
Study 31554628 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐cigarette use (vaping)
Number of subjects: 36
Study 31554628 — intervention group
Group type: COMPARATOR
Intervention: Abstention
Number of subjects: 36
Study 31554628 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable‐power tank users
Number of subjects: 36
Study 28665210 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal depression screening
Number of subjects: 2494
Study 28665210 — intervention group
Group type: COMPARATOR
Intervention: Routine referrals
Number of subjects: 2494
Study 26020673 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based fluid boluses (15 mL/kg)
Number of subjects: 127
Study 26020673 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid boluses for shock or oliguria
Number of subjects: 127
Study 26020673 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid responsiveness (defined as ≥ 15% increase in cardiac index)
Number of subjects: 127
Study 23957281 — intervention group
Group type: EXPERIMENTAL
Intervention: Context shifts during an experience
Number of subjects: 0
Study 23957281 — intervention group
Group type: EXPERIMENTAL
Intervention: Across-item associative processing disruption
Number of subjects: 0
Study 23957281 — intervention group
Group type: EXPERIMENTAL
Intervention: Making order memory judgments
Number of subjects: 0
Study 21685380 — intervention group
Group type: EXPERIMENTAL
Intervention: WM training tasks
Number of subjects: 48
Study 21685380 — intervention group
Group type: COMPARATOR
Intervention: Control tasks
Number of subjects: 48
Study 18469279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (12 mg/d)
Number of subjects: 49
Study 18469279 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (800 mg/d)
Number of subjects: 49
Study 18469279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein + DHA
Number of subjects: 49
Study 18469279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 16554387 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise withdrawal (n = 20)
Number of subjects: 40
Study 16554387 — intervention group
Group type: COMPARATOR
Intervention: Continue regular exercise (n = 20)
Number of subjects: 40
Study 15648984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 60
Study 15648984 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 60
Study 15648984 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 60
Study 11299816 — intervention group
Group type: EXPERIMENTAL
Intervention: SK-1 administered intravenously at dosages of 2, 4, or 10 mg three times.
Number of subjects: 0
Study 9165140 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate, 40 mg qid
Number of subjects: 129
Study 9165140 — intervention group
Group type: COMPARATOR
Intervention: Cisapride, 5 mg tid
Number of subjects: 129
Study 9165140 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 129
Study 9165140 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 129
Study 9582620 — intervention group
Group type: EXPERIMENTAL
Intervention: Chin-cap
Number of subjects: 60
Study 9582620 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular headgear
Number of subjects: 60
Study 9582620 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 3037813 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated Japanese encephalitis vaccine
Number of subjects: 0
Study 3037813 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of vaccine in the second year
Number of subjects: 0
Study 27841057 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR) program
Number of subjects: 198
Study 27841057 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 198
Study 27025442 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cooling sessions per day (5CS)
Number of subjects: 24
Study 27025442 — intervention group
Group type: COMPARATOR
Intervention: 8 cooling sessions per day (8CS)
Number of subjects: 24
Study 24286226 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand therapy for 16 weeks
Number of subjects: 50
Study 24286226 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic regimen nonacog alfa 100 IU kg(‐1) once weekly
Number of subjects: 50
Study 24286226 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic regimen nonacog alfa 50 IU kg(‐1) twice weekly
Number of subjects: 50
Study 22462348 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity intervention group (30 subjects)
Number of subjects: 60
Study 22462348 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 subjects)
Number of subjects: 60
Study 20675638 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality randomized clinical trials (RCTs) in orthopaedic surgery
Number of subjects: 0
Study 20675638 — intervention group
Group type: COMPARATOR
Intervention: Barriers to conducting RCTs
Number of subjects: 0
Study 18703328 — intervention group
Group type: EXPERIMENTAL
Intervention: Pari Boy device with 0.4 micromol/L capsaicin
Number of subjects: 65
Study 18703328 — intervention group
Group type: EXPERIMENTAL
Intervention: Pari Boy device with 2.0 micromol/L capsaicin
Number of subjects: 65
Study 18703328 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxin MA3 device with 0.06 micromol/L capsaicin
Number of subjects: 65
Study 18703328 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxin MA3 device with 0.3 micromol/L capsaicin
Number of subjects: 65
Study 16294204 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-assisted ILM peeling
Number of subjects: 24
Study 16294204 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone-assisted posterior vitreous removal
Number of subjects: 24
Study 16294204 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 24
Study 12796769 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (mean dosage 14.6 mg, max 20 mg)
Number of subjects: 52
Study 12796769 — intervention group
Group type: COMPARATOR
Intervention: Losartan (mean dosage 48 mg, max 50 mg)
Number of subjects: 52
Study 12796769 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 52
Study 12796769 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 52
Study 10980076 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer review meetings with feedback on prescribing behaviour for asthma treatment.
Number of subjects: 199
Study 10980076 — intervention group
Group type: COMPARATOR
Intervention: Peer review meetings with feedback on prescribing behaviour for urinary tract infections (control group).
Number of subjects: 199
Study 10213547 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (10 mg three times daily)
Number of subjects: 218
Study 10213547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 1391262 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of natural porcine surfactant (Curosurf)
Number of subjects: 343
Study 1391262 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of natural porcine surfactant (Curosurf)
Number of subjects: 343
Study 3755640 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg X kg‐1
Number of subjects: 30
Study 3755640 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 1.0 mg X kg‐1
Number of subjects: 30
Study 3755640 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.75 mg X kg‐1
Number of subjects: 30
Study 29572291 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX-hold group
Number of subjects: 316
Study 29572291 — intervention group
Group type: COMPARATOR
Intervention: MTX-continue group
Number of subjects: 316
Study 27743849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder neck intussusception
Number of subjects: 48
Study 27743849 — intervention group
Group type: COMPARATOR
Intervention: Nonintussusception (Control)
Number of subjects: 48
Study 23539942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ska game practice (50 minutes per day, three sessions per week for 16 weeks)
Number of subjects: 40
Study 23539942 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study 21722894 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg daily for the first month followed by 4 mg twice daily for 11 months
Number of subjects: 70
Study 21722894 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 70
Study 21722894 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 70
Study 19520905 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose spiral computed tomography (LDCT)
Number of subjects: 2472
Study 19520905 — intervention group
Group type: COMPARATOR
Intervention: Control (yearly medical examination only)
Number of subjects: 2472
Study 17968939 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy
Number of subjects: 31
Study 15498545 — intervention group
Group type: EXPERIMENTAL
Intervention: IUGR newborns
Number of subjects: 12
Study 15498545 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control newborns
Number of subjects: 12
Study 11423271 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) KIU bolus followed by 5 x 10(5) KIU/h during surgery)
Number of subjects: 38
Study 9494025 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training at 60% of peak oxygen uptake for 8 weeks
Number of subjects: 46
Study 9494025 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 46
Study 9494025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 46
Study 8055389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (2-g single dose)
Number of subjects: 111
Study 8055389 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (standard prophylactic regimen)
Number of subjects: 111
Study 8055389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 111
Study 8055389 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 111
Study 8055389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan and Cefoxitin
Number of subjects: 111
Study 2662130 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline, 5 mg
Number of subjects: 24
Study 2662130 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline, 200 mg
Number of subjects: 24
Study 2662130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of terbutaline and theophylline
Number of subjects: 24
Study 2662130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31476413 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmonella Typhi vaccination (0.025 mg; Typhim Vi, Sanofi Pasteur, UK)
Number of subjects: 40
Study 31476413 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study 27527240 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (25, 50, 100 mg once daily at night for 1 week)
Number of subjects: 147
Study 27527240 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (25, 50, 100 mg twice daily for 1 week)
Number of subjects: 147
Study 27527240 — intervention group
Group type: COMPARATOR
Intervention: Comparison of amitriptyline and lamotrigine
Number of subjects: 147
Study 25428751 — intervention group
Group type: EXPERIMENTAL
Intervention: Endo-Sof™ double‐pigtail ureteral stent, Cook Medical
Number of subjects: 90
Study 25428751 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Durometer loop stent, Bioteq
Number of subjects: 90
Study 25428751 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaris™ Ultra ureteral stent, Boston Scientific
Number of subjects: 90
Study 23098325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol 100/10 μg
Number of subjects: 472
Study 23098325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol 250/10 μg
Number of subjects: 472
Study 23098325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol (both doses)
Number of subjects: 472
Study 21219298 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 47
Study 21219298 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 47
Study 19797133 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin group
Number of subjects: 101
Study 19797133 — intervention group
Group type: COMPARATOR
Intervention: Control group (antibiotic discontinuation strategy according to guidelines)
Number of subjects: 101
Study 22372513 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) initiated at 30 mg, titrated in 20 mg increments to a maximum of 70 mg over 4-5 weeks.
Number of subjects: 28
Study 16026400 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (low-molecular-weight heparin)
Number of subjects: 42